The loss of Chembio Diagnostics under GAAP for the 3 months of 2022 was $8.79 million, up 95.3% from $4.5 million in the previous year. Revenue increased 2.2-fold to $18.817 million from $8.724 million a year earlier.
The loss of Chembio Diagnostics under GAAP for the 3 months of 2022 was $8.79 million, up 95.3% from $4.5 million in the previous year. Revenue increased 2.2-fold to $18.817 million from $8.724 million a year earlier. 
English (US) 